Investigating the effect of traditional persian medicine product based on almond on migraine
Phase 3
- Conditions
- Migraine.Migraine without aura [common migraine]G43.0
- Registration Number
- IRCT20230501058036N1
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Suffering from a migraine headache with the approval of a neurologist
Signing an informed consent form
Age 15 to 45 years
Exclusion Criteria
Pregnant and lactating women
Addiction to cigarettes and drugs
Simultaneous use of other drugs such as antiepileptics, benzodiazepines, barbiturates
Simultaneously suffering from chronic liver, kidney, heart and other neurological diseases except migraine
Unwillingness to continue cooperation
Failure to follow the correct way of taking the prescribed medicine
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of headache. Timepoint: At the beginning of the study, 2, 4 after starting and 2 weeks after finishing the drug. Method of measurement: Visual Analogue Scale, The short Form Health Survey, Headache Impact Test-6.
- Secondary Outcome Measures
Name Time Method Quality of Life. Timepoint: At the beginning of the study, 2-4 weeks after starting and 2 weeks after finishing the drug. Method of measurement: Visual Analogue Scale, The short Form Health Survey, Headache Impact Test-6.;Number of attacks. Timepoint: Number of attacks per week. Method of measurement: Questione.;Duration of headache. Timepoint: Number of attacks per week. Method of measurement: Question.